18 related articles for article (PubMed ID: 38748739)
1. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience.
Aggarwal P; Satapathy S; Sood A; Singh H; Mittal BR; Lal S; Gupta R; Das CK; Yadav TD; Walia R
Clin Nucl Med; 2024 Jul; 49(7):e312-e318. PubMed ID: 38769655
[TBL] [Abstract][Full Text] [Related]
2. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Singh S; Hope TA; Bergsland EB; Bodei L; Bushnell DL; Chan JA; Chasen BR; Chauhan A; Das S; Dasari A; Del Rivero J; El-Haddad G; Goodman KA; Halperin DM; Lewis MA; Lindwasser OW; Myrehaug S; Raj NP; Reidy-Lagunes DL; Soares HP; Strosberg JR; Kohn EC; Kunz PL;
J Natl Cancer Inst; 2023 Sep; 115(9):1001-1010. PubMed ID: 37255328
[TBL] [Abstract][Full Text] [Related]
3. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.
Das S; Chauhan A; Du L; Thomas KE; Jacob A; Schad A; Jain S; Jessop A; Shah C; Eisner D; Cardin DB; Ciombor KK; Goff LW; Bradshaw M; Delbeke D; Sandler M; Ramirez RA; Berlin J
JAMA Netw Open; 2022 Jan; 5(1):e2144170. PubMed ID: 35044469
[TBL] [Abstract][Full Text] [Related]
4. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
5. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy.
Strosberg JR; Al-Toubah T; Pellè E; Smith J; Haider M; Hutchinson T; Fleming JB; El-Haddad G
J Nucl Med; 2021 Jan; 62(1):69-72. PubMed ID: 32444368
[TBL] [Abstract][Full Text] [Related]
6. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort.
Heckert JM; Kipnis ST; Kumar S; Botterbusch S; Alderson A; Bennett B; Creamer C; Eads JR; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Katona BW
Oncologist; 2020 Jul; 25(7):572-578. PubMed ID: 32141667
[TBL] [Abstract][Full Text] [Related]
7. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with
Strosberg J; Kunz PL; Hendifar A; Yao J; Bushnell D; Kulke MH; Baum RP; Caplin M; Ruszniewski P; Delpassand E; Hobday T; Verslype C; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Paganelli G; Severi S; Morse M; Metz DC; Ansquer C; Courbon F; Al-Nahhas A; Baudin E; Giammarile F; Taïeb D; Mittra E; Wolin E; O'Dorisio TM; Lebtahi R; Deroose CM; Grana CM; Bodei L; Öberg K; Polack BD; He B; Mariani MF; Gericke G; Santoro P; Erion JL; Ravasi L; Krenning E;
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2372-2382. PubMed ID: 32123969
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options.
Merola E; Prasad V; Pascher A; Pape UF; Arsenic R; Denecke T; Fehrenbach U; Wiedenmann B; Pavel ME
Neuroendocrinology; 2020; 110(6):517-524. PubMed ID: 31484182
[TBL] [Abstract][Full Text] [Related]
9. Eruption of Metastatic Paraganglioma After Successful Therapy with
Wolf KI; Jha A; van Berkel A; Wild D; Janssen I; Millo CM; Janssen MJR; Gonzales MK; Timmers HJKM; Pacak K
Nucl Med Mol Imaging; 2019 Jun; 53(3):223-230. PubMed ID: 31231443
[TBL] [Abstract][Full Text] [Related]
10. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
12. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
13. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
Zappa M; Hentic O; Vullierme MP; Lagadec M; Ronot M; Ruszniewski P; Vilgrain V
Endocr Connect; 2017 Jan; 6(1):33-38. PubMed ID: 28069898
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
